Comparative efficacy and safety of Pitavastatin 2mg daily and Atorvastatin 10mg daily in patients with dyslipidemia: A systematic review and meta-analysis
Tóm tắt
Background
Statins are effective treatment of dyslipidemia although difference in chemical structure and pharmacokinetics can lead to variations in effects and adverse event profiles. Pitavastatin is found to be effective concerning mean change in lipid profile and offer low drug to drug interaction when compared to equipotent dosages of other statins.
Methods
A meta-analysis of RCT to comparative efficacy and safety of Pitavastatin 2 mg daily versus Atorvastatin 10 mg in patients with dyslipidemia. Comprehensive search of electronic databases was conducted. Primary outcome was percent change from baseline in LDL-C, HDL, TC and TG levels estimated using mean difference in percent changes from baseline lipid profiles. Secondary outcome was overall incidence of statin related adverse events estimated using inverse variance risk ratio. Data analysis were performed using Review Manager version 5.3.
Results
Effect of Pitavastatin did not differ from Atorvastatin on lowering levels of LDL-C (mean difference 1.12; 95% CI -0.54 – 2.81; I2 0%; p 0.19), TC (mean difference 1.71; 95% CI -0.07 – 3.5; I2 42%; p 0.06) and TG (mean difference -1.71; 95% CI -7.08 – 3.66; I2 62%; p 0.53) but was superior in increasing levels of HDL (mean difference 2.26; 95% CI 1.48 – 3.03; I2 0%; p <0.00001). Risk of adverse events did not differ between Pitavastatin and Atorvastatin (RR 0.99; 95% CI 0.76 – 1.28; I2 0%; p 0.92).
Conclusion
Findings suggests that Pitavastatin and Atorvastatin have comparable efficacy in lowering LDL-C, TC and TG as well as safety in the treatment of dyslipidemia. Pitavastatin was superior to Atorvastatin in increasing levels of HDL.
